Understanding how CD33 receptor signaling affects Alzheimer's disease
Mechanism of CD33 receptor signaling in Alzheimer disease
This study is looking at how a specific receptor in the brain, called CD33, affects the way immune cells respond to harmful protein buildup in Alzheimer's disease, with the goal of finding new ways to help clear these proteins and improve the health of patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Southern California NIH-funded |
| Lab location | 1 site (Los Angeles, UNITED STATES) |
| Project ID | NIH-11089513 on NIH RePORTER |
What this research studies
This research investigates the role of the CD33 receptor in the immune response to amyloid-β peptide accumulation in Alzheimer's disease. It focuses on how microglia, the brain's immune cells, respond to these peptide aggregates, which can either protect the brain or contribute to inflammation and damage. By exploring the signaling mechanisms of CD33, the study aims to identify potential therapeutic strategies that could enhance the clearance of harmful amyloid-β and improve patient outcomes. The research employs advanced techniques to analyze the structure and function of CD33 and its interactions with amyloid-β.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at risk of developing it due to genetic or environmental factors.
Not a fit: Patients with other forms of dementia unrelated to amyloid-β accumulation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that enhance the brain's ability to clear amyloid-β, potentially slowing the progression of Alzheimer's disease.
How similar studies have performed: Previous research has shown promising results in targeting immune modulation for Alzheimer's disease, suggesting that this approach could be effective.
Where this research is happening
Los Angeles, UNITED STATES
- University of Southern California — Los Angeles, United States (Active)
Researchers
- Principal investigator: Ulmer, Tobias Sebastian — University of Southern California
- Study coordinator: Ulmer, Tobias Sebastian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.